Star Health’s underwriting turnaround and 15–16% growth glidepath

Star Health and Allied Insurance Company Limited — Q1 FY2027 Earnings Call (held on July 30, 2026)

1. Overall Tone of Management: Optimistic

• Management highlights “fourth successive quarter of improvement in core underwriting profitability” and frames results as “further evidence” that the “course correction” is being sustained.
• Uses confident forward language: “should gradually increase” (insurance revenue growth) and “mid- to high-teen ROE” glide path.
• However, they also add some caution/hedging around seasonality and lack of explicit loss-ratio guidance (see Q&A).

2. Key Themes from Management Commentary

• Profitable growth focus (risk-first underwriting + preferred segments):
• “disciplined and prudent risk selection” and “avoidance of riskier pools.”
• Strategy explicitly tied to ROE thresholds and portfolio optimization.
• Underwriting improvement is sustained:
• Underwriting result: Rs. 111 crore vs Rs. 16 crore YoY.
• CISR improved to 97% (from 98.7%).
• “fourth successive quarter” of improvement.
• GST waiver tailwind continues to support category growth and fresh business:
• Management calls affordability impact “very evident,” with “majority of fresh business emerging from first-time buyers.”
• Distribution advantage via proprietary channels:
• Proprietary agency + digital D2C contributed “90% plus” of retail business.
• Agency scale: ~20,000 new agents in the quarter; total 8.5 lakh; 19% YoY improvement in productivity.
• D2C momentum: D2C fresh business grew 142% YoY, 98% new-to-insurance.
• Claims and wellness/telemedicine as a structural lever:
• Telemedicine/home healthcare described as improving management of “fever and infection-related cases.”
• Watchful stance for Q2 infectious disease seasonality, but claims support is “on hand.”
• Technology/AI as cost + fraud/waste control engine:
• “layering generative AI” over existing AI/ML for claims precision.
• AI/ML already showing “encouraging results” on fraud/waste/abuse mitigation.
• Profit normalization to reduce mark-to-market volatility:
• Introduced/continued “normalised PAT” framework pegged to 8% normalised annual investment yield.

3. Q&A Analysis

Theme A: Growth translation (GWP vs insurance revenue) + seasonality

• Core questions
• Why insurance revenue growth (13.4%) lags GWP growth (19%); when will they converge?
• How to think about growth given higher claim season (vector-borne diseases) in Q2?
• Management response
• Insurance revenue growth should “gradually increase” and “start touching 15-16%” as long-term policy effects normalize.
• For seasonality: infectious disease incidence is expected to rise, but they are “on track” due to wellness/telemedicine/home healthcare.
• Notable signals
• No hard quantitative guidance beyond the 15–16% “touching” comment; reliance on long-term policy accounting dynamics.

Theme B: Loss ratio improvement drivers + sustainability

• Core questions
• What levers drive the loss ratio improvement from here?
• Is improvement driven by telemedicine, pricing, fraud/waste, or mix?
• Is loss ratio improvement likely to continue or is back-book deterioration possible?
• Management response
• Levers reiterated as “360-degree approach”: portfolio quality, pricing, claims initiatives (network management, wellness, teleconsultation), fraud/waste/abuse controls.
• Telemedicine scale-up is now “starting to give us some good results.”
• They explicitly corrected one analyst misunderstanding: 30–40 bps improvement guidance was for expense ratio, not loss ratio.
• For sustainability: “trajectory will continue” but “work-in-progress” and “not a destination.”
• Evasive/partial elements
• They refused to provide a loss ratio guidance and did not quantify the waterfall (frequency vs severity vs FWA vs mix).
• Telemedicine impact is acknowledged but not quantified vs “two years back” (only qualitative “huge scale-up”).
• One analyst asked for dengue/malaria loss ratio ballparks; management only said Q2 is typically higher and expected to continue.

Theme C: Expense ratio, acquisition costs, and regulatory commission/EoM

• Core questions
• Further expense ratio improvement: stabilize or continue?
• Acquisition expense efficiency and whether regulatory commission reforms will help.
• Reinsurance impact on expense ratio (Schedule 6 not disclosed).
• Management response
• Expense ratio improvement target: 30–40 bps improvement “consistently over the years” (stated by CFO).
• Acquisition expense: they operate within regulatory limits; will “await and see” regulatory guidelines for clarity.
• Reinsurance: voluntary quota share treaty impact fading; obligatory reinsurance negotiations with GICRE may bring benefits; reinsurance cost should “keep on coming down.”
• Notable signals
• Stronger clarity on expense ratio than on loss ratio.
• Regulatory commission reforms: they won’t comment on proposed regulation specifics but emphasize they’re “uniquely placed” due to ~90% proprietary distribution.

Theme D: Repricing strategy (annual pricing, cohorts)

• Core questions
• How much of the book gets repriced in Q1 vs throughout the year?
• Whether pricing is “adequate” or requires step-ups in certain cohorts.
• Management response
• Annual pricing calendar; repricing impact flows through earned premiums over subsequent quarters.
• “Most pricing action… has been in Q4 over the last couple of years.”
• Pricing strategy is “maintenance,” “no knee-jerk reactions,” and based on actuarial evaluation.
• Evasive elements
• No cohort-level repricing percentages provided for Q1 FY27; only general calendar mechanics.

Theme E: Accounting/IFRS technical clarifications (DAC, time value, PAA vs others)

• Core questions
• Why there is “insurance contract” finance income/expense under PAA (time value of money).
• DAC outstanding not visible on balance sheet; how to reconcile.
• Management response
• Finance component explained as “time value of money” due to cash upfront for long-term contracts.
• DAC reconciliation described as non-straightforward; depends on multiple components (fresh/new, digital, short-term vs long-term).
• Notable signals
• Management offered to explain “one-to-one” offline—suggesting limited transparency in-call.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Insurance revenue growth outlook: should “gradually increase” and “start touching 15-16%” (from Q1’s 13.4%).
• Expense ratio improvement: “30–40 basis points improvement in the expense ratio… consistently over the years.”
• ROE glide path (qualitative but with numeric range): “mid- to high-teen ROE” (no specific year-by-year number).
• Reinsurance cost range (qualitative-to-quantitative): full-year FY27-28 reinsurance expense “in the range of 0.5%, 0.6%” (asked as a forward build).
• Normalised PAT framework: normalised annual investment yield pegged at 8% (methodology guidance).

Implicit signals (qualitative)

• Loss ratio: no explicit guidance; management implies improvement is “work-in-progress” and “trajectory will continue,” but they avoid committing to a target number.
• Seasonality management: expect Q2 infectious disease seasonality to be higher, but telemedicine/home healthcare should keep outcomes “on track.”
• Pricing: “maintenance” pricing approach; annual repricing rhythm; no “knee-jerk” step-ups unless actuarially required.
• Regulatory reforms: they expect potential advantage from proprietary distribution if commission/EoM reforms come.

5. Standout Statements (direct / revealing)

• Sustained underwriting turnaround: “fourth successive quarter of improvement in core underwriting profitability.”
• Expense vs loss ratio clarity correction: “comment… was not about loss ratio improvement. It was about expense ratio improvement.”
• Telemedicine impact timing: “huge scale-up has been achieved quarter to quarter… starting to give us some good results.”
• Growth convergence expectation: insurance revenue growth “should gradually increase… start touching 15-16%.”
• ROE glide path: “mid- to high-teen ROE… glide path… moving in that direction over the last three to four quarters.”
• Loss ratio stance (no destination): “it is a work-in-progress all the time… not a destination.”
• Reinsurance cost direction: “reinsurance cost as a business will keep on coming down.”
• Accounting explanation (time value): finance component arises from “time value of money” due to cash upfront for long-term contracts.

6. Red Flags / Positive Signals

Positive signals
– Clear operational metrics improvement: CISR down, underwriting profit up sharply, CAGR-like fresh growth with high new-to-insurance mix.
– Management repeatedly ties underwriting improvement to repeatable levers (pricing discipline, fraud/waste controls, wellness/telemedicine).
– Expense ratio improvement guidance is specific (30–40 bps), and they emphasize staying within regulatory EoM limits.

Red flags
– Loss ratio guidance gap: despite strong improvement, they refuse to guide loss ratio quantitatively.
– Attribution remains qualitative: no quantified waterfall (frequency vs severity vs FWA vs mix) despite repeated analyst asks.
– Telemedicine quantified only broadly: “huge scale-up” but limited comparative numbers vs “two years back” in this call.
– Accounting complexity: multiple offline offers for DAC/reconciliation and technical finance income under PAA—can reduce confidence for investors seeking transparency.

7. Historical Comparison & Consistency Analysis (vs prior 3–4 calls)

a. Change in Tone Over Time

• Current (Q1 FY27): more confident on underwriting sustainability (“fourth successive quarter,” “course correction… sustained”).
• Prior calls:
• Q4 & FY26 (Apr 29, 2026): already optimistic about turnaround; emphasized “green shoots” and underwriting profit turning positive.
• Q3 & 9M FY26 (Jan 29, 2026): optimistic but more about “corrective actions” and early improvement; less about “sustained” multi-quarter streak.
• Q2 & H1 FY26 (Oct 29, 2025): tone was improving but still framed as execution and recalibration; less “sustained” language.
• Classification: More Optimistic than earlier periods.
• What changed: management now leans harder on multi-quarter consistency and provides expense ratio and insurance revenue growth directional numbers, while still avoiding loss ratio targets.

b. Tracking Past Commitments vs Outcomes

• Past statement (Q4 & FY26): normalized PAT framework pegged at 8% and underwriting turnaround sustained.
• Outcome in Q1 FY27: normalized PAT concept reiterated; underwriting profitability continues improving (underwriting result Rs. 111 crore; “fourth successive quarter”).
• Flag: ✅ Delivered (methodology and sustained improvement narrative holds).
• Past statement (Q4 & FY26 / earlier): telemedicine/home healthcare interventions scaling to mitigate infectious disease seasonality.
• Outcome in Q1 FY27: telemedicine described as “huge scale-up” and “starting to give… good results,” with Q2 watchfulness.
• Flag: ✅ Delivered (directionally; still not fully quantified).
• Past statement (Q2 & H1 FY26 / Q3 FY26): expect continued loss ratio improvement trajectory.
• Outcome: loss ratio improvement continues, but management still won’t commit to a numeric target (e.g., 65–66%).
• Flag: ⏳ Partially delivered (improvement exists, but target achievement not confirmed).

c. Narrative Shifts

• From “turnaround” to “durable advantage”:
• Earlier calls emphasized recalibration and early green shoots.
• Now it’s framed as “durable underwriting and service advantage” with AI layering and sustained underwriting profitability.
• Loss ratio attribution remains broad:
• Despite repeated Q&A, they still avoid a precise waterfall—suggesting either complexity or reluctance to lock in explanations.

d. Consistency & Credibility Signals

• Credibility: Medium-High
• Consistent themes across calls: risk-first underwriting, pricing discipline, telemedicine/home healthcare, fraud/waste controls, proprietary distribution.
• Consistency in refusing loss ratio numeric guidance while providing expense/operational directional guidance.
• Some “confidence” statements are supported by multi-quarter improvement metrics, but attribution remains qualitative.

e. Evolution of Key Themes

• Demand/growth: structurally positive narrative persists (GST waiver tailwind + first-time buyers). Now management also expects insurance revenue growth to converge upward.
• Margins/cost: expense ratio improvement guidance becomes more explicit in Q1 FY27.
• Claims management: telemedicine shifts from “initiative” to “results starting to show.”
• Regulatory: commission/EoM reforms discussed as “wait and see,” but proprietary distribution is positioned as an advantage.

f. Additional Insights (cross-period intelligence)

• Increasing defensiveness on loss ratio explanation: analysts repeatedly ask for quantified levers; management keeps it at “360-degree approach,” and corrects misinterpretations (expense vs loss).
• Accounting complexity is becoming a recurring friction point: DAC/reconciliation and PAA finance income questions appear again; management continues to offer offline explanations rather than in-call clarity.